Zerbaxa Approval History
- FDA approved: Yes (First approved December 19th, 2014)
- Brand name: Zerbaxa
- Generic name: ceftolozane and tazobactam
- Dosage form: Injection
- Company: Cubist Pharmaceuticals, Inc.
- Treatment for: Intraabdominal Infection, Urinary Tract Infection
Zerbaxa (ceftolozane and tazobactam) is a cephalosporin and beta-lactamase inhibitor combination for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI).
Development History and FDA Approval Process for Zerbaxa
|Dec 19, 2014||FDA Approves Zerbaxa (ceftolozane/tazobactam) for Complicated Intra-Abdominal/Urinary Tract Infections|
|Apr 23, 2014||Cubist Announces Submission of NDA for Investigational Antibiotic Ceftolozane/tazobactam|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.